LJN452D
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.2M | 52 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 52 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO | NOVARTIS PHARMACEUTICALS CORPORATION | $9,079 | 0 |
Top Doctors Receiving Payments for LJN452D
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Albuquerque, NM | $1.2M | 52 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 0
- Transactions 52
About LJN452D
LJN452D is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 52 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $1.2M was paid across 52 transactions to 0 doctors.
The most common payment nature for LJN452D is "Unspecified" ($1.2M, 100.0% of total).
LJN452D is associated with 2 research studies, including "A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO" ($1.1M).